NovoSeven RT® (coagulation factor VIIa [recombinant])

NovoSeven RT is authorized only for treatment, perioperative management, or prophylaxis of bleeding in the listed indications — hemophilia A/B with inhibitors, acquired hemophilia (adults only), congenital Factor VII deficiency, and Glanzmann's thrombasthenia (must be refractory to platelet transfusion) — limited to the FDA‑approved and specified off‑label compendial uses; all other uses are excluded. Authorization requires documentation of the specific diagnosis and indication, prescription or consultation by a hematologist/hemophilia specialist, IV administration with adherence to the policy’s weight‑based mcg/kg dosing and dosing documentation, and is granted for up to 12 months.

"Treatment of bleeding episodes in adults and children with hemophilia A with inhibitors (FDA‑approved)."

Sign up to see full coverage criteria, indications, and limitations.